Journal News

Sibling study reveals mechanism for genetic disease

Ken Hallenbeck
Feb. 13, 2024

Genetic diseases pass from parents to children — often in surprising ways. The unpredictability of these transfers means that sometimes a disease skips whole generations, while other times it may affect only one sibling. Pairs of affected and unaffected siblings provide a unique opportunity for scientists to study the molecular mechanisms of genetic disease.

Unraveling the connection between the genetic mutation a person carries and the symptoms they have has been a decades-long focus of Yi-Wen Chen’s laboratory, part of the Center for Genetic Medicine Research at Children’s National Hospital in Washington, D.C. Chen’s expertise is in genetic muscle disorders, which occur in 59 out of every 100,000 adults in the United States.

Muscle weakness can sometimes start early – even in the womb. Other times, as is the case with the second-most common muscle disorder, adult-onset facioscapulohumeral muscular dystrophy, or FSHD, symptoms begin much later, in adolescence or early adulthood. Why is this, and does it hint at a way to design treatment?

To answer these questions, Chen’s laboratory teamed up with proteomics expert Jatin Burniston of the Research Institute for Sport and Exercise Sciences at Liverpool John Moores University. They studied affected and unaffected sibling pairs using proteomics experiments designed to reveal the underlying mechanisms of FSHD.

The researchers took cell cultures from each sibling and incubated them with deuterium, or “heavy water.” Then, they tracked the lifespan of each protein in the cell with mass spectrometry. The results, described in a recent article in Molecular & Cellular Proteomics, implicate slower turnover of mitochondrial proteins, but more abundant mitochondrial proteins in the sibling with FSHD. Slower turnover means old proteins — which should be recycled — pile up in the mitochondria, triggering stress responses and interrupting normal cell function. The finding is a clever combination of atomic-level detail and good biological controls.

Yusuke Nishimura, a postdoctoral research associate in Burniston’s lab was a co-first author on the paper.

“Mitochondrial dysfunction and mitochondrial stress in FSDH had been identified in previous studies,” Nishimura said. However, that information alone wasn’t enough to begin designing a treatment. Because FSHD varies widely between individuals, “studying (the) underlying biological mechanisms is challenging,” he said.

Differences in protein turnover observed when comparing FSDH patients with healthy individuals may not be caused by the disease, but simply be normal variances between unrelated people. That’s where the sibling pair comes in — by simultaneously analyzing a sibling with FSHD and a sibling without the disease, Nishamura and collaborators were able to unravel the FSHD mystery.

FSHD has no treatment or cure. “Our new data on mitochondrial protein dynamics in FSHD is particularly exciting because highlighting dysfunctions in protein turnover offers a potential new therapeutic route,” Nishimura said.

Next, researchers must find a way to increase protein recycling in the mitochondria and test if the improved turnover relieves FSHD symptoms. To do so, they need to develop better mouse models of FSHD. If the evidence continues to mount, therapeutic strategies such as targeted protein degradation might be used to restore order to the mitochondria in FSHD patients.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ken Hallenbeck

Ken Hallenbeck earned a Ph.D. in pharmaceutical sciences from the University of California, San Francisco, and now is an early drug-discovery researcher. He serves on the board of directors of ReImagine Science and is the life sciences lead at TerraPrime.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Antibiotic sensor directly binds drug in resistant bacteria
Journal News

Antibiotic sensor directly binds drug in resistant bacteria

Oct. 8, 2025

Researchers at Drexel University uncover how the vancomycin-resistant bacterial sensor binds to the antibiotic, offering insights to guide inhibitor design that restores antibiotic effectiveness against hospital-acquired infections.

ApoA1 reduce atherosclerotic plaques via cell death pathway
Journal News

ApoA1 reduce atherosclerotic plaques via cell death pathway

Oct. 1, 2025

Researchers show that ApoA1, a key HDL protein, helps reduce plaque and necrotic core formation in atherosclerosis by modulating Bim-driven macrophage death. The findings reveal new insights into how ApoA1 protects against heart disease.

Omega-3 lowers inflammation, blood pressure in obese adults
Journal News

Omega-3 lowers inflammation, blood pressure in obese adults

Oct. 1, 2025

A randomized study shows omega-3 supplements reduce proinflammatory chemokines and lower blood pressure in obese adults, furthering the understanding of how to modulate cardiovascular disease risk.

AI unlocks the hidden grammar of gene regulation
Feature

AI unlocks the hidden grammar of gene regulation

Sept. 30, 2025

Using fruit flies and artificial intelligence, Julia Zeitlinger’s lab is decoding genome patterns — revealing how transcription factors and nucleosomes control gene expression, pushing biology toward faster, more precise discoveries.

Zebrafish model links low omega-3s to eye abnormalities
Journal News

Zebrafish model links low omega-3s to eye abnormalities

Sept. 24, 2025

Researchers at the University of Colorado Anschutz developed a zebrafish model to show that low maternal docosahexaenoic acid can disrupt embryo eye development and immune gene expression, offering a tool to study nutrition in neurodevelopment.

Top reviewers at ASBMB journals
Observance

Top reviewers at ASBMB journals

Sept. 19, 2025

Editors recognize the heavy-lifters and rising stars during Peer Review Week.